SEARCH:   Advanced

Blood, Vol. 113, Issue 19, 4497-4504, May 7, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood Baccarani et al. 113: 4497 Supplemental materials for: Baccarani et al Files in this Data Supplement: Table S1. Inclusion criteria (PDF, 14.6 KB) Table S2. Definition of hematologic response (HR) and cytogenetic response (CgR) (PDF, 10.3 KB) - CgR was defined based on chromosome banding analysis of at least 20 marrow metaphases. If marrow cell metaphases were not available, a CCgR was defined by less than 1% positive signals by fluorescence-in-sity-hybridization (FISH) of at least 200 marrow cell interphase nuclei. Table S3. List of the laboratories where molecolar biology studies were performed, along with conversion factor (PDF, 21.7 KB) This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020